Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors, Key Messages
PDF | English
Image For Activity Cover
Credit Offered
No Credit Offered
The CAP Pathology and Laboratory Quality Center, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology collaboratively developed this evidence-based guideline, consensus statements, clinical tools and resources related to the practice of lung cancer pathology and laboratory medicine, oncology, and molecular diagnostics. Through this work, these organizations and their members continually educate stakeholders and advance the quality of diagnostic medicine to improve lung cancer patient outcomes. Read about the key messages related to the guideline.
Powered By